Cannabigerol
Viewing r1 — May 12, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
CBG (cannabigerol) is a cannabinoid of the terpenophenol class. It is the biosynthetic precursor to THC, CBD, and all major phytocannabinoids — known as "the mother of cannabinoids." It acts on the brain's cannabinoid system and serotonin receptors, but with too little potency at any single target to produce intoxication or euphoria.
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
CBG was first isolated from hashish in 1964 by Yehiel Gaoni and Raphael Mechoulam. It attracted little research for decades — in most plants, it converts entirely to THC and CBD before harvest. Cultivar breeding and the 2018 U.S. hemp legalization pushed CBG from obscurity to one of the most marketed minor cannabinoids, with fourteen registered clinical trials by 2026.[1]
Subjective effects include anxiety reduction, stress relief, and mild improvement in verbal memory.[1] The experience is defined by what it lacks — no intoxication, no perceptual changes, no euphoria, no cognitive impairment. Effects are so subtle that subjects in the only controlled human trial could not reliably distinguish CBG from placebo; no characteristic unsought effects have been identified at tested doses.
CBG produces no known physical dependence, and no lethal dose has been established in any species. The primary risk signal is chronic liver damage observed in rats at low doses[2] — though human liver cells ranked CBG as the least toxic among tested cannabinoids.[3] The compound is better understood as a therapeutic candidate than a safety-characterized substance — no human pharmacokinetic or toxicity data have been published.
History[edit]
Discovery
Cannabigerol was first isolated from hashish in 1964 by Yehiel Gaoni and Raphael Mechoulam.[4][5] It was one of the earliest cannabinoids to be structurally identified. But it fell into obscurity: in most cannabis plants, its precursor is almost entirely converted to THC, CBD, and CBC during growth, leaving CBG at less than 1% of dry weight.[6]
Biosynthetic Significance
CBG's precursor, CBGA, is the starting material for every major cannabinoid class.[6][5] Three dedicated enzymes convert it into the acid precursors of THC, CBD, and CBC.[7] CBG accumulates only in cultivars that lack functioning versions of these enzymes.
Modern Emergence
Research accelerated after 2010, driven by high-CBG cultivar breeding, yeast fermentation methods that produce CBG without cannabis plants,[8] and the 2018 U.S. Farm Bill legalizing hemp-derived cannabinoids. By 2026, fourteen clinical trials are registered and the first published human RCT appeared in 2024 — more than sixty years after initial isolation.[1]
The name cannabigerol combines Cannabis, geranyl (the terpene building block in its structure), and the -ol suffix marking its phenolic hydroxyl group. The designation "mother of cannabinoids" — found in scientific literature and marketing alike — reflects CBGA's role as the metabolic starting point for THC, CBD, and CBC.
Chemistry[edit]
Structural Class
CBG belongs to the terpenophenol class. Its structure consists of an aromatic resorcinol ring with a linear ten-carbon geranyl chain — open and uncyclized, unlike THC and CBD, which close that chain into rings during biosynthesis.[9] This open geranyl structure distinguishes CBG pharmacologically and is thought to underlie both its antibacterial activity and its liver oxidative signal.[2]
Molecular Properties and Natural Occurrence
CBG has the molecular formula C₂₁H₃₂O₂ (molecular weight 316.5 g/mol). It has no chirality centers — unlike THC and CBD, which gain them when their chains cyclize into rings.
In most cannabis cultivars, CBG remains below 1% of dry weight because CBGA is rapidly converted to downstream cannabinoid acids during plant maturation;[6] specialized cultivars can accumulate CBG above 10%.[7] Yeast fermentation using engineered Saccharomyces cerevisiae provides an agricultural-independent production route.[8]
Pharmacology[edit]
Mechanism of Action
Cannabinoid Receptors
CBG is a weak partial agonist at CB1 and CB2 receptors, with binding affinity estimated at 10–100 times lower than THC.[10] This weak binding is the structural reason CBG cannot produce a high.[11] Animal studies confirm mild pain suppression and anxiolysis consistent with low-level CB1 activation, including activity at CB1/CB2 receptor complexes.[12]
TRP Channels, Serotonin, and Endocannabinoid System
CBG's strongest receptor interactions are at pain-sensing TRP channels: it activates and desensitizes TRPV1 and TRPV2 while blocking TRPM8, the cold-sensing receptor.[13] In joint tissue, it also activates TRPA1 channels.[14] Computational modeling predicts partial agonism at serotonin receptors,[15] consistent with observed anxiolytic effects, and α2-adrenergic receptor activity has also been reported.[16]safety citation needed CBG also inhibits anandamide reuptake, raising the brain's own endocannabinoid tone at synapses.[13]
Pharmacokinetics
No published human pharmacokinetic data exist for CBG.safety citation needed The only species-level data come from an equine study[17] and cannot be extrapolated to humans. The specific liver enzymes responsible for CBG metabolism are unknown, creating a direct gap in drug interaction assessment.safety citation needed
Neuroscience[edit]
Where It Acts
CBG elevates the brain's own cannabinoid signaling by slowing anandamide reuptake at synapses.[13] This indirect approach — enhancing the brain's own system rather than overwhelming it — likely explains why CBG's effects are so subtle. In animal models of multiple sclerosis, Huntington's disease, and stroke, CBG reduced inflammatory markers in brain immune cells and protected neurons.[18][19][20]
Why It Matters
The single published human trial found that 20 mg oral CBG improved verbal memory[1] — an unexpected result, since THC reliably impairs it. This may reflect anandamide modulation at concentrations too low to strongly activate CB1, fine-tuning memory circuits rather than disrupting them. CBG's broad interactions across multiple receptor systems predict moderate, widely distributed effects that are difficult to attribute to any single mechanism.
No brain imaging studies have measured CBG's receptor occupancy at any dose, making it impossible to determine which targets actually drive clinical effects. Whether CBG produces lasting neuroplastic changes — as THC and psilocybin do through distinct mechanisms — has not been investigated.
Subjective Effects[edit]
CBG's experiential character is defined by absence. At the one dose tested in humans, it reduces anxiety and stress without producing any change in perception, thinking, or consciousness — effects so faint that subjects in the only controlled trial could not reliably distinguish it from placebo.[1]
Within the cannabinoid class, CBG sits closest to CBD — non-intoxicating and physiologically subtle — but with a distinct pharmacological signature: stronger cold-receptor blockade, a pro-mnemonic effect CBD does not share, and weaker endocannabinoid enzyme inhibition. Compared to THC, it is experientially inert.
Effect Grid
At 20 mg oral — the only dose tested in a human randomized controlled trial — CBG produces measurable anxiety suppression and stress reduction without any detectable subjective drug effects. Verbal memory is mildly enhanced relative to placebo. There is no intoxication, no altered consciousness, no euphoria or cognitive impairment. Users cannot reliably distinguish CBG from placebo on standard drug-effect scales.
Physically, no body high, sedation, motor control impairment, or somatic effects were detected at this dose. CBG is sub-perceptual in the conventional psychoactive sense — its effects register on validated anxiety and cognition instruments but not on subjective experience measures.
The 20 mg dose point comes from a single crossover trial (n=34, Cuttler 2024). No dose-response relationship has been established in humans.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Nausea suppression · Sedation
Timeline
Sub-perceptual absorption phase. CBG does not produce detectable first alerts — onset is defined pharmacologically rather than experientially. As a lipophilic cannabinoid, oral absorption begins within 30-90 minutes.
Maximum pharmacological activity. Anxiety suppression and mild memory enhancement are measurable on validated instruments but remain sub-perceptual — users cannot distinguish active drug from placebo on subjective scales.
Gradual return to baseline. No comedown effects, rebound anxiety, or residual impairment reported at 20 mg oral. CBG does not impair motor function or cognition at tested doses.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Moderate
- Withdrawal
- None
- Tolerance buildup
- none
- Tolerance reset
- —
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- —
Toxicity
Acute Toxicity
No lethal dose has been established for CBG in any species.safety citation needed The single human trial (20 mg oral) and a topical safety study both reported no adverse events.[1][8]
Chronic Liver Toxicity
In a 90-day rat study, oral CBG at doses as low as 0.66 mg/kg/day caused liver damage: tissue changes, disrupted blood cell counts, altered liver enzyme levels, and oxidative stress.[2] The open geranyl chain in CBG's structure was proposed as the chemical cause of this oxidative disruption.[2]
Liver toxicity signals were observed at very low doses (0.66 mg/kg/day) in a 90-day chronic exposure model. Human relevance has not been established, but these findings warrant caution regarding long-term CBG use, particularly in individuals with pre-existing liver conditions.
A contrasting result comes from human cell-derived liver models: CBG ranked as the least hepatotoxic among tested cannabinoids, with CBN, CBD, and CBC all showing greater liver toxicity potential.[3] Neither finding alone settles CBG's liver safety.
Cell Toxicity at High Concentrations
At high concentrations in laboratory studies, CBG was highly toxic to brain immune cells, dramatically increasing inflammatory markers and reactive oxygen species.[21] DNA damage was detected at moderate-to-high concentrations in one assay but not another,[21] and toxicity was also observed in neuronal cell cultures.[22] These concentrations are substantially higher than those expected at therapeutic doses.
Psychological Risks
No psychological adverse effects have been reported in human studies.[1] CBG does not produce the anxiety, paranoia, or psychotic symptoms that can occur with THC. No data exist on psychological effects at higher doses or with chronic use.
Tolerance and Dependence
No studies have characterized CBG tolerance, dependence, or withdrawal in any species.safety citation needed Cannabis dependence is primarily driven by CB1 adaptation from sustained THC exposure; CBG's weak CB1 activity makes this adaptation unlikely. The human trial found no reinforcing or psychoactive effects at 20 mg oral,[1] though formal abuse liability testing has not been conducted.
Drug Interactions
No published drug interaction studies for CBG exist.safety citation needed CBG is presumably metabolized by liver CYP enzymes, but the specific enzymes involved are unknown.safety citation needed CBG demonstrates synergistic pain-relieving effects with other non-intoxicating cannabinoids (CBD, CBC, CBDV) through calcium channel mechanisms.[23]
Contraindications
No contraindication data specific to CBG have been published.safety citation needed The following are inferred from available evidence:
- Liver conditions: The rat study demonstrating liver damage at 0.66 mg/kg/day[2] warrants caution in those with pre-existing liver disease, elevated liver enzymes, or concurrent use of liver-toxic medications.
- CYP-metabolized medications: Cannabinoid-class enzyme inhibition is plausible but uncharacterized for CBG.safety citation needed
- Pregnancy and breastfeeding: No reproductive or developmental toxicity data exist. Use during pregnancy or lactation cannot be recommended.
- Children and adolescents: No safety data exist for minors.
Harm Reduction[edit]
Forms & Identification
CBG is primarily sold as oral tinctures, capsules, and oils from high-CBG hemp cultivars or through extraction. Full-spectrum products contain trace amounts of other cannabinoids and terpenes; isolate products contain CBG alone.
The main identification concern is not CBG counterfeiting — the compound has no recreational value that would motivate it — but undisclosed THC content in hemp-labeled products. Third-party certificates of analysis from accredited labs are the only reliable way to verify cannabinoid content, THC levels, and the absence of heavy metals, pesticides, and residual solvents.
Guidelines
- Start with a low dose and increase gradually. The only controlled human data exist at 20 mg oral — effects at higher doses are uncharacterized.
- Use products with current, third-party certificates of analysis confirming cannabinoid content and THC levels below legal thresholds.
- If using CBG for a specific purpose (anxiety, sleep, pain), keep a brief written log of dose, timing, and perceived effects to evaluate personal response over time.
- Avoid long-term daily use until more chronic safety data are available, given the hepatotoxic signals observed in animal studies.
- If taking prescription medications, consult a healthcare provider — CBG's drug interaction profile is entirely uncharacterized.
Set & Setting
CBG does not produce intoxication or altered consciousness at tested doses, making set and setting less critical than with psychoactive cannabinoids. Because effects are subtle and often sub-perceptual, a consistent routine and environment helps in evaluating whether the compound produces a noticeable personal response.
Aftercare & integration. CBG does not produce altered states requiring integration. For those taking CBG for anxiety or stress management, periodic reassessment is more useful than post-session processing.
Evaluate whether sustained use produces the intended benefit, note any changes in sleep, appetite, or mood over weeks rather than hours, and adjust dosing or discontinue if no benefit is apparent.
Recovery & Support
No dependence syndrome or withdrawal pattern has been documented for CBG. If CBG use has become part of a broader pattern of cannabinoid or supplement dependence, general substance use support resources may help.
SAMHSA's National Helpline (1-800-662-4357) provides free referrals. For those using CBG alongside THC products where THC dependence is a concern, cannabis-specific support communities and counseling services can address the broader pattern.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
CBG emergencies are unlikely given its non-intoxicating profile, but adverse reactions to contaminated or mislabeled products are possible.
Recognizing an emergency: Severe allergic reaction (difficulty breathing, facial swelling, hives), signs of liver distress with chronic use (yellowing of skin or eyes, severe abdominal pain, dark urine), or any reaction inconsistent with a non-psychoactive cannabinoid — which may indicate product contamination or mislabeling.
Immediate steps:
- 1. Stop taking the product immediately.
- 2. If breathing difficulty or swelling occurs, call emergency services.
- 3. Retain the product and its packaging for identification.
- 4. If symptoms suggest THC intoxication (anxiety, rapid heartbeat, disorientation), move to a calm, safe environment and wait — effects will resolve.
What to tell the dispatcher: Name the substance (cannabigerol/CBG), the amount taken, when it was taken, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help.
Legal Status[edit]
CBG's legal status is determined entirely by broader hemp and cannabis laws — no country or international body has scheduled CBG specifically.[24]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Legal (hemp-derived) | Federally legal under the 2018 Farm Bill when derived from hemp containing ≤0.3% Δ9-THC dry weight. Not scheduled. State-level regulations vary[24] |
| United Kingdom | Legal (hemp-derived) | Legal from EU-approved industrial hemp strains with <0.2% THC. Products must not make unapproved medical claims[24] |
| European Union | Legal (hemp-derived) | Legal from EU-approved hemp strains with <0.2% THC. Member states may impose additional restrictions[24] |
| Canada | Regulated (Cannabis Act) | Regulated under the Cannabis Act. Legal when compliant with Cannabis Regulations[24] |
| Australia | Legal (hemp-derived) | Legal from hemp with <0.3% THC under TGA regulations. Cannabis-derived CBG may be controlled[24] |
Legal status for hemp-derived cannabinoids changes frequently. The information above reflects 2025–2026 law. Always verify current jurisdiction-specific regulations before purchasing or using CBG products. This is not legal advice.
CBG is not detectable by standard drug tests targeting THC metabolites. However, commercial CBG products may contain trace THC, which could trigger positive results on immunoassay screens. Third-party certificates of analysis are the primary method for verifying purity.
references
- [1]
- [2]
- [3] ^abGao X, Campasino K, Yourick MR, et al. (2024) Comparison on the mechanism and potency of hepatotoxicity among hemp extract and its four major constituent cannabinoids — Toxicology doi:10.1016/j.tox.2024.153885
- [4]
- [5] ^abHanus LO, Meyer S, Munoz E, Taglialatela-Scafati O, Appendino G (2016) Phytocannabinoids: a unified critical inventory — Natural Product Reports doi:10.1039/c6np00074f
- [6] ^abcAndre CM, Hausman JF, Guerriero G (2016) Cannabis sativa: The Plant of the Thousand and One Molecules — Frontiers in Plant Science doi:10.3389/fpls.2016.00019